Quality of life assessment in Spanish lung cancer patients by the EORTC questionnaires

Oncologia

Volumn 28, Issue 4, 2005, Pages 12-20

  Arraras Urdaniz, J I ^a   Martinez Aguillo M ^a   Manterola Burgaleta, A ^a   Salgado Pascual, E ^a   Martinez Lopez E ^a   Vera Garcia R ^a   Illarramendi Manas J J ^a  

^a Instituto de Investigación Sanitaria de Navarra   (Spain)

Author keywords

Chemotherapy; Lung cancer; Quality of life valuation; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER THERAPY; CLINICAL FEATURE; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; TOXICITY;

EID: 20644435786     PISSN: 03784835     EISSN: None     Source Type: Journal    
DOI: 10.4321/S0378-48352005000400002     Document Type: Article

References (34)

1. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 1993; 11: 1866-1872.
2. Herndon JE, Fleishman S, Kornblith AB, Kosty M, Green MR, Holland J. Is quality of life predictive of the survival of patients with advanced non-small cell lung carcinoma? Cancer 1999; 85: 333-340.
3. Helsing M, Bergman B, Thaning L, Hero U. Quality of Life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy plus carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Eur J Cancer 1998; 34: 1036-1044.
4. Hürny C, Bernhard J, Joss R et al. Feasibility of Quality of Life assessment in a randomized phase III trial of small cell lung cancer. A lesson from the real world. The Swiss Group for Clinical Cancer Research SAKK. Ann Oncol 1992; 3: 825-831.
5. Gower NH, Rudd RM, Ruiz de Elvira MC et al. Assessment of Quality of Life using a daily diary card in a randomised trial of chemotherapy in small cell lung cancer. Ann Oncol 1995;6:575-580.
6. Joss RA, Alberto P, Hürny C et al. Quality versus quantity of life in the treatment of patients with advanced small cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. The Swiss Group for Clinical Cancer Research SAKK. Ann Oncol 1995; 6: 41-48.
7. Giaconne G, Splinter TA, Debruyne C et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1998; 16: 2133-2141.
8. Sundstrom S, Bremnes R, Aasebo U et al. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. J Clin Oncol 2004; 22(5):801-180.
9. Mantovani G, Astara G, Manca G et al. Endoscopic laser ablation as palliative treatment of endobronchial, nonresectable, or recurrent lung cancer: assessment of its impact on quality of life. Clin Lung Cancer 2000; 1(4):277-285
10. Langendijk H, de Jong J, Tjwa M et al. External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomized study. Radiother Oncol 2001; 58(3):257-268.
11. Smith IE, O'Brien ME, Talbot DC et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001; 1;19(5):1336-1343.
12. Aaronson NK, Ahmezdai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a Quality of Life instrument for use in intentional clinical trials. J Natl Cancer Inst 1993; 85: 365-376.
13. Aaronson NK, Cull A, Kaasa S, Sprangers M. The EORTC modular approach to Quality of Life assessment in Oncology. Int J Ment Health 1994; 23: 75-96.
14. Kiebert GM, Kaasa S. Quality of Life in clinical trials: experience and perspective of the European Organization for Research and Treatment of Cancer. J Natl Cancer Inst 1993; 20: 91-95.
15. Sprangers MAG, Cull A, Bjordal K, Groenvold M, Aaronson NK. The European Organization for Research and Treatment of Cancer approach to Quality of Life assessment: guidelines for developing questionnaire modules. Qual Life Res 1993; 2: 287-295.
16. Sprangers M, Groenvold M, Arraras JI et al. The European Organization for Research and Treatment of Cancer Breast Cancer-Specific Quality of Life questionnaire module: first results from a three-country field study. J Clin Oncol 1996; 14: 2756-2768.
17. Arraras JI, Arias F, Tejedor M et al. El cuestionario de Calidad de Vida para tumores de cabeza y cuello de la EORTC QLQ-H&N35. Estudio de validación para nuestro país. Oncología 2001; 24(10):482-491.
18. Arraras JI, Vera R, Manterola A et al. El cuestionario de Calidad de Vida para cancer colorectal EORTC QLQ-CR38. Estudio de validación para nuestro país. Oncología 2003; 26(9):285-292
19. Bjordal K, de Graeff A, Payers PM et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. Eur J Cancer 2000; 36: 1796-1807.
20. Kaasa S, Bjordal K, Aaronson NK et al. The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. Eur J Cancer 1995; 31A: 2260-2263.
21. Porzsolt F, Wolpl CP, Rist CE, Kosa R, Buchele G, Gaus W. Comparison of 3 instruments (QLQ-C30, SF-36, QWB-7) measuring health related quality of life quality of well-being. Psych Oncol 1996; 5: 103-117.
22. Zieren HU, Muller JM, Hamberger U, Pichlmaier H. Quality of Life after surgical therapy of bronchogenic carcinoma. Eur J Cardiothorac Surg 1996; 10: 233-237.
23. McMillan DC, Wigmore SJ, Fearon KC, O'Gorman P, Wright CE, McArdle CS. The use of megestrol acetate in the treatment of weight loss in gastrointestinal cancer patients with weight loss. Br J Cancer 1999; 79: 495-500.
24. Bergman B, Aaronson NK, Ahmezdai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC core Quality of Life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 1994; 30A: 635-642.
25. Montazeri A, Gillis CR, McEwen J. Quality of Life in patients with lung cancer. A review of literature from 1970 to 1995. Chest 1998; 113: 467-481.
26. Gridelli C, Perrone F, Nelli F et al Quality of life in lung cancer patients. Ann Oncol 2001;12 Suppl 3:S21-25.
27. Arraras JI, Tejedor M, Arias F et al. El Grupo de Calidad de Vida de la EORTC. Estudios del Servicio de Oncología del Hospital de Navarra dentro de este organismo. Oncología 2000; 23(6):302-306
28. Folstein M, McHugh PR. Mini-mental state: a practical method for adding the cognitive state of patients for the clinician. J Psy Res 1975; 12: 189-198.
29. Arraras JI, Pruja E, Tejedor M, Illarramendi JJ, Dominguez MA, Valerdi JJ. El cuestionario de Calidad de Vida de la EORTC, QLQ-C30 (versión 2.0). Estudio estadístico de validación para nuestro país con pacientes con cáncer de pulmón. Rev Oncología 1999; 1: 257-263.
30. Arraras JI, Pruja E, Marcos M et al. El cuestionario de Calidad de Vida para cáncer de pulmón de la EORTC QLQ-LC13. Estudio de validación para nuestro país. Oncología 2000; 23: 127-134.
31. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948; 1: 634-656.
32. NCI Common toxicity criteria. National Cancer Institute, Division of Cancer Treatment, 1988.
33. Valerdi JJ, Tejedor M, Molina F et al. Combined treatment with induction chemotherapy and hyperfractionated radiotherapy for the treatment of stage III non-small cell lung cancer. Proc ASCO 1996; 408.
34. Hopwood P, Harvey A, Davies J et al. Survey of the administration of Quality of Life questionnaires in three multicentre randomised trials in cancer. Eur J Cancer 1998; 34: 49-59.